Clinical Study of Weifuchun Treatment on Precancerous Lesions of Gastric Cancer

• Status: Unknown status
• Trial end date: 2019-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Research purpose To elucidate the effect mechanism and clinical effective of weifuchun in the prevention and treatment of chronic atrophic gastritis and precancerous lesions of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of weifuchun's treatment on chronic atrophic gastritis, reversing precancerous lesions of gastric cancer.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ShuGuang Hospital
• Treatments: Vitamins

Criteria

Inclusion Criteria:

1. Patients with chronic atrophic gastritis and precancerous lesions according to the pathological findings under gastroscope

2. Helicobacter pylori(-)

Exclusion Criteria:

1. Patients with Helicobacter pylori positive infection without radical treatment.

2. Patients with peptic ulcer, severe dysplasia or suspected malignant transformation.

3. Pregnant or lactating women and those who are pregnant and may not have effective contraception.

4. Patients with severe heart, lung, gallbladder, kidney, endocrine, hematopoietic system and neuropsychiatric diseases should not be included in this study.

5. Allergic constitution or known ingredients of this medicine.

6. Patients with other tumors.

7. Patients participating in other clinical trials within 1 month.

8. Patients with severe cirrhotic ascites and portal hypertension.

9. Other diseases that interfered with the study were deemed unsuitable for the patients included in the study.